Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS) Clinical Trial

Official title:
A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)

Status Completed

Clinical Trial Summary

The purpose of the study is to assess the efficacy of ravulizumab to control disease activity in children and adolescents with aHUS who have not previously used a complement inhibitor (complement inhibitor treatment-naïve), as well as in complement inhibitor-experienced (eculizumab-experienced) adolescent participants.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Atypical Hemolytic Uremic Syndrome
Atypical Hemolytic Uremic Syndrome (aHUS)
Azotemia
Hemolysis
Hemolytic-Uremic Syndrome
Syndrome

Clinical Trial Details

NCT number	NCT03131219
Study type	Interventional
Source	Alexion Pharmaceuticals, Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	August 31, 2017
Completion date	December 20, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01755429` - To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients	N/A
Completed	`NCT01757431` - The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)	Phase 2
Not yet recruiting	`NCT06312644` - Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Completed	`NCT02949128` - Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)	Phase 3
Completed	`NCT01770951` - A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)